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HIV-1 Nef, a critical AIDS progression factor, repre-
sents an important target protein for antiretroviral
drug discovery. Because Nef lacks intrinsic enzy-
matic activity, we developed an assay that couples
Nef to the activation of Hck, a Src family member
and Nef effector protein. Using this assay, we
screened a large, diverse chemical library and identi-
fied small molecules that block Nef-dependent Hck
activity with low micromolar potency. Of these, a di-
phenylpyrazolo compound demonstrated submicro-
molar potency in HIV-1 replication assays against a
broad range of primary Nef variants. This compound
binds directly to Nef via a pocket formed by the Nef
dimerization interface and disrupts Nef dimerization
in cells. Coupling of nonenzymatic viral accessory
factors to host cell effector proteins amenable to
high-throughput screening may represent a general
strategy for the discovery of new antimicrobial
agents.
INTRODUCTION
The year 2011 marked the 30th anniversary of the HIV/AIDS
pandemic with 25 million AIDS-related deaths worldwide and
33 million people infected with the virus. The course of the
disease changed dramatically with the advent of antiretroviral
drugs, which target HIV-1 enzymes critical to the viral life cycle
as well as fusion of the virus with the host cell (Temesgen
et al., 2006). Although cocktails of these drugs have extended
the life expectancy of infected individuals, they do not clear the
virus and require lifelong administration. Chronic drug therapy,
coupled with the remarkable mutational capacity of HIV-1,
continues to drive drug resistance (Gupta et al., 2009). The emer-
gence of multidrug-resistant strains of HIV-1, together with
uncertain prospects for an effective vaccine, underscores the
urgent need for new antiretrovirals with mechanisms of action
complementary to existing agents.82 Chemistry & Biology 20, 82–91, January 24, 2013 ª2013 ElsevierIn addition to viral enzymes and structural proteins, the HIV-1
genome encodes a unique set of accessory factors (Vpr, Vpu,
Vif, and Nef) that are essential for viral pathogenesis and repre-
sent underexplored targets for new antiretroviral drug discovery
(Malim and Emerman, 2008). HIV-1 Nef is particularly attractive
in this regard because it enhances HIV infectivity, promotes viral
replication, and enables immune escape of HIV-infected cells
(O’Neill et al., 2006; Joseph et al., 2005). Nef lacks known
biochemical activity, functioning instead through interactions
with a myriad of host cell proteins. These interactions provide
a molecular basis for many Nef functions, including downregula-
tion of viral (CD4/CXCR4/CCR5) and immune (MHC-I) receptors
from the host cell surface. Nef-mediated receptor internalization
is believed to prevent superinfection and enhance viral release,
whereas MHC-I downregulation promotes evasion of immune
surveillance by the host.
A critical role for Nef in HIV disease has also been established
in animal models as well as patients with AIDS. Nef is required for
the high-titer replication of both HIV and SIV in vivo and is essen-
tial for the development of AIDS-like disease in nonhuman
primates (Geyer et al., 2001; Arold and Baur, 2001; Kestler
et al., 1991). Furthermore, targeted expression of Nef in the
T cells and macrophages of transgenic mice induces a severe
AIDS-like syndrome, strongly supporting an essential role for
this single viral protein in HIV-1 pathogenesis (Hanna et al.,
1998; Jolicoeur, 2011). The phenotype of these Nef-transgenic
mice recapitulates many aspects of human AIDS, including
profound immunodeficiency, loss of CD4+ T cells, thymic
atrophy, persistent T cell activation, as well as kidney, spleen,
and lung pathology. In contrast, HIV strains with defective nef
alleles have been isolated from patients with long-term, nonpro-
gressive HIV infections (Kirchhoff et al., 1995; Deacon et al.,
1995). Similarly, CD4+ T cell depletion and immunosuppression
were greatly delayed in a cohort of individuals infected with
a Nef-deficient HIV-1 quasispecies, providing strong clinical
evidence that Nef is essential for disease progression in humans
(Dyer et al., 1997; Deacon et al., 1995). Taken together, these
findings provide a strong rationale for the discovery and devel-
opment of Nef-directed antiretroviral drugs.
Identification of small molecule Nef antagonists as drug leads
has been hampered by the lack of an assay for Nef functionLtd All rights reserved
Figure 1. HTS for Inhibitors of Nef-Dependent Hck Activity
TheNIHMLSCN library (220,000 compounds) was screened using the FRET-
based Nef:Hck in vitro kinase assay as described in the text.
(A) Scatterplot of results from a representative 384-well plate is shown. Under
these conditions, Hck is inactive when added by itself (blue circles), whereas
addition of a 10-fold molar excess of Nef induces Hck kinase activation,
demonstrating the Nef dependence of the assay (red circles). Compounds
(Comp) were screened at 20 mM under conditions where Hck activity is
completely dependent on Nef (gray circles), with >50% inhibition defined as
a ‘‘hit’’ (dashed line).
(B) Z0 factors for each 384-well plate for the entire HTS campaign are shown. Of
694 plates screened, 684 passed with Z0 factors R0.5 (98.5% pass rate);
plates that failed due to robotic error were rescreened and subsequently
passed (see also Table S1).
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HTS for HIV-1 Nef Antagonistscompatible with high-throughput screening (HTS). Previously,
we reported the development of an in vitro kinase assay that
couples Nef to the activation of the Src family kinase (SFK),
Hck (Emert-Sedlak et al., 2009). Hck is strongly expressed in
macrophages, a major HIV-1 host cell type, and serves a key
effector role in Nef-dependent HIV-1 replication and downregu-
lation of MHC-I (Narute and Smithgall, 2012; Dikeakos et al.,
2010; Emert-Sedlak et al., 2009; Atkins et al., 2008). Using this
assay to screen a small kinase-biased library, we identified
a unique diphenylfuranopyrimidine (DFP) kinase inhibitor that
also blocks Nef-dependent HIV-1 replication (Narute and Smith-
gall, 2012; Emert-Sedlak et al., 2009). In the present study, we
automated this kinase-coupled Nef assay, enabling HTS of
a much larger and more diverse chemical library of more than
220,000 compounds. Subsequent concentration-response
experiments identified a subset of 62 compounds with low
micromolar potency for Nef-dependent kinase activation. OfChemistry & Biology 20,these, four compounds emerged that potently inhibit both
HIV-1 infectivity and replication inmultiple cell lines. In particular,
we discovered a unique diphenylpyrazolo compound that
inhibits Nef-dependent HIV-1 replication with submicromolar
potency. This compound is broadly active against HIV-1 replica-
tion supported by Nef alleles representative of all major subtypes
of HIV-1. Furthermore, surface plasmon resonance (SPR)
studies show that this compound binds to Nef at a site formed
at the Nef dimerization interface, supporting a mechanism of
action involving direct interaction with the viral protein. These
studies demonstrate that coupling Nef to Hck, a natural host
cell effector kinase amenable to HTS, enables discovery of direct
small molecule antagonists for this critical HIV virulence factor.
This kinase-coupling strategy may be more generally useful for
other drug discovery targets where direct assays are not readily
available.
RESULTS AND DISCUSSION
HTS for Direct Nef Antagonists
Previously, we described a screening assay for inhibitors of Nef-
dependent SFK activation (Emert-Sedlak et al., 2009). Imple-
mentation of this assay on a pilot scale with a kinase-biased
library identified 4-amino-substituted DFPs as potent inhibitors
of Nef-dependent SFK activation and HIV replication (Narute
and Smithgall, 2012; Emert-Sedlak et al., 2009). One critical
feature of this screening assay is that Hck kinase activation is
completely dependent upon Nef, thereby providing a functional
readout of Nef activity in vitro. We reasoned that screening
a larger andmore diverse compound library with this assaymight
identify compounds that bind directly to Nef rather than the
active site of Hck, which is the likely mechanism of action of
the DFP compounds (Emert-Sedlak et al., 2009).
Using the Nef-coupled kinase assay, we screened the NIH
Molecular Library Screening Center Network (MLSCN) collection
of more than 220,000 diverse chemical structures. This fully
automated HTS campaign yielded 364 confirmed ‘‘hit’’ com-
pounds with IC50 values for Nef-induced Hck activation of less
than 20 mM (overall hit rate of 0.1%; Table S1 available online).
Assay results from a representative plate are shown in Figure 1A
and illustrate that kinase activity is entirely dependent upon Nef.
Overall, nearly 700 3 384-well plates were screened, with
a composite Z0 factor (Zhang et al., 1999) of 0.83 ± 0.12, indica-
tive of a remarkably robust HTS assay (Figure 1B). Interest-
ingly, the DFP inhibitors of Nef-dependent Hck activation
first identified in the pilot screen described above were also
flagged as active in the large-scale screen. All 364 hit com-
pounds were then reassayed in ten-point concentration-
response assays against Nef-induced Hck versus Hck alone.
These experiments identified 66 compounds with at least a 3-
fold preference for inhibition of Nef-activated Hck (Tables S1
and S2). These compounds were then assayed for anti-HIV
activity as well as cytotoxicity in U87MG astroglioma cells (Fig-
ure S1) and CEM-T4 lymphoblasts (Figure S2). Our previous
work has established that HIV replication is dependent upon
Nef in both of these cell lines (Narute and Smithgall, 2012;
Emert-Sedlak et al., 2009). In U87MG cells, 24 of the 62
compounds (39%) showed more than 50% inhibition of HIV-1
replication at a concentration of 1 mM without toxicity. The82–91, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 83
Figure 2. Inhibitors of Nef-Dependent Hck
Activity Also Block Nef-Dependent HIV
Replication and Infectivity
(A) Chemical structures of the compounds
identified by the Nef:Hck HTS campaign and
subsequently shown to block Nef-dependent
enhancement of HIV-1 replication in two different
cell lines are shown, along with the IC50 values for
each compound against Hck alone versus the
Nef:Hck complex. Two compounds from the
screen share a diphenyldiazenylpyrazole sub-
structure (highlighted in red), differing only in the
placement of a single chlorine atom.
(B) HIV replication is presented. Compounds
(1 mM) shown in (A) were added to cultures of
U87MG and CEM-T4 cells in 96-well plates, fol-
lowed by infection with wild-type HIV-1 NL4-3 (50
pg p24 equivalents/ml) 1 hr later. Viral output for
the DMSO-treated control cultures was consis-
tently greater than 100-fold over the HIV input,
typically ranging from 9,000 to 12,000 p24 equiv-
alents/ml. Virus replication was assessed by p24
ELISA after 4 days (U87MG) or 9 days (CEM-T4).
Data are expressed as the mean percent inhibition
as compared to control cultures incubated with
the carrier solvent (DMSO) ± SEM (n = 4). Results
of replication and cytotoxicity experiments with all
66 hit compounds from the primary screen are
shown in Figures S1 and S2.
(C) Infectivity assays are illustrated. Compounds
(3 mM) were added to cultures of the reporter cell
line TZM-bl followed by infection with either wild-
type or Nef-defective (DNef) HIV NL4-3 in 96-well
plates. After 48 hr, relative virus infectivity was
assessed as luciferase production in infected
cells. Results are plotted as the mean percentage
of HIV-1 infectivity observed in control cells
incubated with the carrier solvent DMSO ± SEM
(n = 3). In the absence of Nef, infectivity is reduced
by about 50% (DNef; dashed line shown for
reference).
See also Figures S1 and S2.
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HTS for HIV-1 Nef Antagonistsresponse rate in CEM-T4 cells was somewhat lower, with 11 of
the 62 hit compounds (18%) blocking replication by more than
50% under the same conditions. Five compounds inhibited
HIV-1 replication in both cell lines with low-to-submicromolar
potency and without appreciable cytotoxicity. The structures of
these compounds, their IC50 values for inhibition of the Hck:Nef
complex versus Hck alone, as well as their effects on HIV-1 repli-
cation are shown in Figure 2.
Because HIV-1 Nef is also known to enhance HIV-1 infectivity
(Vermeire et al., 2011; Spina et al., 1994; Chowers et al., 1994;
Aiken and Trono, 1995), we also evaluated the impact of these
five compounds on infectivity using the TZM-bl reporter cell
line (Platt et al., 1998; Derdeyn et al., 2000). In this system, infec-
tivity is measured as stimulation of luciferase reporter gene
expression driven by the HIV-1 LTR in response to infection
with HIV-1, and this effect is enhanced by HIV-1 Nef. As shown
in Figure 2C, four of the five compounds suppressed Nef-depen-
dent enhancement of HIV-1 infectivity, providing further support
for a Nef-directed antiretroviral mechanism of action.84 Chemistry & Biology 20, 82–91, January 24, 2013 ª2013 ElsevierDiphenylpyrazoles Block Nef-Dependent HIV-1
Replication and SFK Activation
Of the five compounds with Nef-dependent anti-HIV activity,
two share a diphenyldiazenylpyrazole substructure, differing
only in the placement of a single chlorine atom (Figure 2A).
Of these, (E)-4-((3-chlorophenyl)diazenyl)-5-hydroxy-3-(4-nitro-
phenyl)-1H-pyrazole-1-carbothioamide, referred to hereafter as
‘‘B9,’’ exhibited remarkable selectivity for Hck inhibition in the
presence of Nef (Figure 3A). B9 blocked the kinase activity of
the Nef:Hck complex in vitro with an IC50 value of 2.8 mM,
whereas its activity against Hck alone was >20 mM. B9 also
showed weak activity against other Src family members
in vitro, with IC50 values >20 mM for c-Src, Lck, and Lyn. Although
these findings support a Nef-dependent mechanism of action,
the possibility of direct action on cellular kinases or other
proteins cannot be formally ruled out.
To investigate whether the antiretroviral activity of B9 was
dependent upon the expression of Nef, we compared the impact
of B9 on replication of wild-type and Nef-defective HIV-1 inLtd All rights reserved
Figure 3. Inhibition of Nef-Dependent Hck Activity and HIV-1
Replication by the Diphenylpyrazolo Compound, B9
(A) Concentration-response curves for B9 were generated with the Nef:Hck
complex (circles) versus Hck alone (squares) using the Z0-LYTE kinase assay.
For Hck alone, approximately 5-foldmore kinase protein was added to achieve
a similar level of activity as the Nef:Hck complex. Under these conditions, B9
inhibits Nef-dependent Hck activation with an IC50 value in the lowmicromolar
range (2.8 mM), whereas the IC50 value for Hck alone is >20 mM. Kinase assays
were performed three times in quadruplicate, and the data represent percent
inhibition as compared to the DMSO vehicle control ± SEM.
(B) CEM-T4 cells were infected with wild-type HIV-1 NL4-3 (gray bars) or the
corresponding Nef-defective mutant (DNef; black bars) in the presence of the
B9 concentrations shown. Viral replication was assessed 9 days later by p24
ELISA. Input virus for HIV-1DNef was increased by 10-fold relative to wild-type
to compensate for the reduced infectivity and replication of Nef-defective virus
in CEM-T4 cells (Narute and Smithgall, 2012). This experiment was done in
triplicate, and data are represented as percentage of HIV-1 replication relative
to the DMSO vehicle control ± SEM.
(C) TZM-bl cells were infected with wild-type (gray bars) and DNef (black bar)
HIV NL4-3 in the presence of the B9 concentrations shown, and infectivity was
assessed as luciferase activity 48 hr later. This experiment was repeated three
times in triplicate, and the data are represented as percent infectivity relative to
the DMSO control ± SEM. In the absence of Nef, infectivity is reduced by about
50% (dashed line shown for reference).
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HTS for HIV-1 Nef AntagonistsCEM-T4 cells. As shown in Figure 3B, B9 blocked wild-type
HIV-1 replication with an IC50 value in the 100–300 nM range,
whereas replication of Nef-defective HIV-1 was unaffected
at the highest concentration tested (3.0 mM). B9 also inhibited
Nef-mediated enhancement of HIV-1 infectivity in a con-
centration-dependent manner in the reporter cell line, TZM-bl
(Figure 3C). Together, these results strongly support a Nef-
dependent antiretroviral mechanism of action for B9.
We next evaluated whether B9 is broadly active against the
diverse Nef alleles that comprise the majority of HIV-1 M-group
clades. For these experiments, we used a set of recombinant
HIV-1 NL4-3 chimeras in which the NL4-3 Nef sequence isChemistry & Biology 20,replaced with representative Nef sequences derived from the
M-group HIV-1 subtypes A1, A2, B, C, F1, F2, G, H, J, K, as
well as the laboratory strain, SF2 (Narute and Smithgall, 2012).
As shown in Figure 4A, B9 inhibited the replication of all 11
HIV-1 Nef chimeras with an IC50 value of 300 nM in CEM-T4
cells, demonstrating that the compound is broadly active against
HIV replication supported by a wide range of HIV-1 Nef proteins.
As observed previously, the compound had no effect on the
replication of Nef-defective HIV replication in this experiment.
Recently, we showed that infection of CEM-T4 cells with HIV-1
causes a sustained increase in endogenous SFK activation that
is dependent upon Nef (Narute and Smithgall, 2012). We there-
fore explored whether the inhibition of Nef-dependent kinase
activation observed with B9 in vitro could also be observed in
inhibitor-treated cells under conditions of viral replication block.
For these studies, CEM-T4 cells were infected with wild-type
HIV-1 NL4-3, the 11 Nef chimeras, and the Nef-defective mutant
in the presence or absence of B9. Endogenous SFK activity was
assessed in infected cell lysates by immunoblotting with an
antibody that recognizes the phosphotyrosine residue in the
activation loop of active SFKs (pY418). As shown in Figure 4B,
wild-type but not Nef-defective HIV infection stimulated endog-
enous SFK activation, consistent with previous results (Narute
and Smithgall, 2012). B9 treatment completely inhibited Nef-
dependent SFK activation at a concentration of 1.0 mM. These
results provide important evidence that B9 blocks Nef-mediated
SFK activation in HIV-infected cells, which may represent one
part of its antiretroviral mechanism of action.
Diphenylpyrazoles Interact Directly with HIV-1 Nef
The data presented above show that the diphenylpyrazole
compound B9 potently inhibits Nef-dependent enhancement
of HIV-1 replication aswell as endogenous SFK activation across
all M-group HIV-1 Nef alleles tested, suggesting that Nef is the
target for this compound in HIV-infected cells. To explore
possible binding sites for B9 on the Nef structure, docking
studies were performed using AutoDock Vina (Trott and Olson,
2010) and the crystal structure of HIV-1 Nef in complex with
a SFK SH3 domain (Protein data Bank [PDB] 1EFN; Lee et al.,
1996). All docking studies used an unbiased approach, with
the grid covering the entire structure of the Nef dimer. This
analysis predicted two energetically favorable binding sites for
B9, one of which localizes to the Nef dimer interface (site 1),
whereas the other maps to the surface of each monomer (site
2; Figure 5A). The predicted binding energy for the Nef dimer
interface (site 1) was more favorable than that for the other site
(8.5 versus 7.2 kcal/mol). Docking of the compound to site
1 is predicted to involve a network of polar contacts with resi-
dues Gln104, Gln107, and Asn126 from both Nef monomers
via a pocket that is formed at the dimer interface (Figure 5B). In
contrast, binding site 2 is shallower and involves a single polar
contact with Asn126. All predicted binding site residues within
4 A˚ of B9 along with the number of B9 conformations accommo-
dated by each site are summarized in Table S3.
To determine whether B9 binds directly to Nef, we next per-
formed SPR studies using immobilized Nef and a range of
compound concentrations. As shown in Figure 6A, B9 interac-
tion with Nef was readily detected by this approach, demon-
strating saturable binding at each B9 concentration tested. The82–91, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 85
Figure 4. Inhibition of HIV-1 Nef Chimera
Replication and Endogenous SFK Activa-
tion in CEM-T4 Cells by the Diphenylpyra-
zolo Compound, B9
(A) CEM-T4 cells (1 3 104 per well of a 96-well
plate) were infected with wild-type (WT) HIV-1
NL4-3, a Nef-defective mutant (DNef), or the indi-
cated Nef chimeras in a final culture volume of
200 ml. Input virus for HIV-1DNef was increased by
10-fold relative to wild-type to compensate for the
reduced infectivity and replication of Nef-defective
virus in CEM-T4 cells (Narute and Smithgall, 2012).
B9 was added to the cultures to final concentra-
tions of 0.3 and 1.0 mM, and viral replication was
determined by p24 ELISA 10 days later. Data are
expressed as the mean percentage of HIV-1
replication observed in control cultures incubated
with the carrier solvent (0.1% DMSO) ± SD (n = 6).
(B) CEM-T4 cells were infected with wild-type
HIV-1 NL4-3, a Nef-defective mutant (DNef), or the
indicated Nef chimeras in a final culture volume of
10 ml in the presence of B9 (1 mM) or the DMSO
carrier solvent as a control (Con). The infected
cells were lysed, and SFK proteins were immu-
noprecipitated with a pan-specific antibody and
protein G-Sepharose beads. The SFK activation
state was assessed by immunoblotting with a
phosphospecific antibody against the activation
loop phosphotyrosine residue common to all Src
family members (pY418). Control blots were per-
formed on cell lysates for HIV-1 Gag proteins (p55,
p40, and p24), Nef, as well as actin as a loading
control. Results from uninfected cells are shown in
the far-right lane (No virus). This experiment was
repeated twice with comparable results.
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HTS for HIV-1 Nef Antagonistsresulting SPR sensorgrams fit a heterogeneous ligand-parallel
reaction model (Kuroki and Maenaka, 2011) (where Nef is
‘‘ligand’’), which yielded KD values of 860 ± 58 nM and 1.72 ±
0.23 nM. These binding data are consistent with the docking
results, which predicted two binding sites (Figure 5). The SPR
data were also consistent with a two-state model, in which B9
binding to a lower-affinity site is predicted to induce a conforma-
tional change to a higher-affinity binding site (Figure 6B). The
overall KD value resulting from this two-state analysis was
1.79 ± 0.11 nM, which is in close agreement with the heteroge-
neous ligand model.
To validate the B9 binding site predicted by AutoDock Vina
(Figure 5), we created a series of three Nef mutants with Ala,
Leu, and Gln substitutions for Asn126, which is predicted to
contact the ligand in both binding sites. Each of these mutants
was expressed and purified in recombinant form and compared
to wild-type Nef in terms of B9 binding by SPR. As shown in Fig-
ure 6C, none of these mutants demonstrated detectable binding
to B9, supporting a critical role for Asn126 in B9 binding. To verify
that the Nef mutants were properly folded, we also performed
SPR analysis with the Hck SH3 domain, which binds to a site
that is dependent upon the three-dimensional (3D) fold of Nef
(Lee et al., 1996) but is distinct from the B9 binding site. All three
Nef mutants bound to the Hck SH3 domain with similar kinetics
and affinities as wild-type Nef, demonstrating that the Asn126
mutations did not cause a global disturbance in the Nef structure
(data not shown). These Nef mutants also activated recombinant86 Chemistry & Biology 20, 82–91, January 24, 2013 ª2013 ElsevierHck to the same extent as wild-type Nef in the in vitro kinase
assay (Figure 6D). The dramatic impact of Nef Asn126 mutagen-
esis on B9 binding may relate to its predicted role in forming
polar contacts with B9 in both predicted binding sites. This
residue is conserved in all of the Nef alleles present in the
HIV-1 Nef chimeras used to demonstrate B9-sensitive viral
replication in Figure 4, consistent with the broad-spectrum
anti-HIV activity observed with this compound.
In addition to HIV-1 Nef, we also performed docking studies of
B9 with a recent X-ray crystal structure of SIV Nef (Kim et al.,
2010). In this structure, SIV Nef also packs as a dimer, although
the nature of the dimer interface is distinct from that of HIV-1 Nef
(Figure S3A). Remarkably, B9 was also predicted to dock to an
energetically favorable site formed by the SIV Nef dimer interface
(Table S3). This result led us to test whether B9 impacts SIV repli-
cation and infectivity. For the replication assay, CEM-174 cells
were infected with the pathogenic SIV quasispecies DB670
(Seman et al., 2000) over a range of B9 concentrations, and
assayed for SIV replication as p27 Gag release. As shown in Fig-
ure S3B, B9 blocked SIV replication with an IC50 value of about
1.0 mM. We also evaluated the impact of B9 on SIV DB670 infec-
tivity using the TZM-bl reporter cell line described above for HIV.
As shown in Figure S3C, B9 blocked SIV infectivity with an IC50
value of about 3 mM. These results provide further support for
the idea that compounds targeting the Nef dimer may be broadly
effective as Nef antagonists. Previous studies have shown that
the Nef dimerization interface is very sensitive to mutagenesis,Ltd All rights reserved
Figure 5. Docking Studies Predict Direct Interaction of B9 with the
HIV-1 Nef Dimer Interface
(A) The two ‘‘halves’’ of the Nef dimer (PDB 1EFN) are modeled in green and
blue, respectively (Nef-A and Nef-B). B9 is docked at the two most energeti-
cally favored binding sites (Sites 1 and 2). The structure of B9 is shown for
reference (right).
(B) Close-up view of the predicted B9 binding sites. Site 1 is more energetically
favored and nestles between the a helices that form the dimer interface. Here,
B9 is predicted to form an extensive network of polar contacts with Nef resi-
dues Gln104, Gln107, and Asn126. Site 2 is positioned on the surface of each
Nef monomer, away from the dimerization interface, and also makes a polar
contact with Asn126. A single site 2 interaction of B9 with the Nef dimer is
shown for simplicity. B9 also docks to the SIV Nef dimerization interface (see
Figure S3).
For additional details of docking results, see Table S3.
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Nef functions related to receptor downregulation and HIV-1
replication (Poe and Smithgall, 2009; Liu et al., 2000). These
studies suggest that small molecules such as B9, which bind
to the dimer interface and influence the conformation or stability
of the dimer, may have a major impact on Nef function.
The Diphenylpyrazole B9 Blocks Nef Dimerization
in Cells
Data presented above demonstrate that B9 binds directly to Nef
and suggest that it may influence Nef dimerization as a mecha-
nism of action. To test this idea, we used a bimolecular fluores-
cence complementation (BiFC) assay previously developed for
Nef in our laboratory (Poe and Smithgall, 2009). In this assay,
Nef is expressed as a pair of fusion proteins with nonfluorescent
fragments of YFP in 293T cells. Nef dimerization juxtaposes theChemistry & Biology 20,YFP fragments, which then refold to form the fluorescent YFP
structure. Nef dimerization requires four conserved hydrophobic
side chains that lock together to form a helical interface (Ile109,
Leu112, Tyr115, Phe121; Figure 7A). Replacement of these
residues with aspartic acid (Nef-4D mutant) results in a dramatic
loss of the Nef-BiFC signal, providing a negative control for the
assay. To test the effect of B9 on Nef dimerization by BiFC,
293T cells were transfected with wild-type Nef-BiFC fusion
proteins and incubated with B9 over a range of concentrations
(1–6 mM). As shown in Figure 7B, B9 treatment resulted in
a concentration-dependent loss in the Nef BiFC signal, with
suppression more dramatic than that observed with the Nef-
4Dmutant at the highest concentration tested (6 mM). All cultures
were immunostained with a Nef antibody to establish that B9
interferes with dimerization rather than Nef protein expression.
These data support the idea that B9 inhibits Nef dimerization
as part of its mechanism of action.
The observation that B9 prevents Nef dimerization suggests
an allosteric mechanism for B9-mediated inhibition of Hck
activation. This raises the question of whether the dimerization
interface contributes to Hck activation in the Z0-LYTE assay,
which was used to discover B9. To test this possibility, the
dimerization-defective Nef-4D mutant was expressed and puri-
fied in recombinant form, and tested for its ability to activate
Hck in the Z0-LYTE assay. Figure 7C shows that Nef-4D is
completely defective for Hck activation in vitro. Previous studies
have shown that recombinant Nef-4D retains its capacity for SH3
domain binding (Poe and Smithgall, 2009), indicating that this
mutation does not globally influence Nef protein folding. These
results support the idea that B9 inhibits Hck activation by binding
to the Nef dimerization interface, thereby preventing Nef dimer-
ization and juxtaposition of associated Hck kinase domains. This
observation complements a previous observation from our
group showing that enforced dimerization of Nef leads to hyper-
activation of Hck in a cell-based system (Ye et al., 2004).
SIGNIFICANCE
Work presented here describes a strategy for the discovery
of small molecule antagonists that interact directly with
Nef, a major virulence factor for HIV-1. Nef lacks intrinsic
biochemical activity and therefore is not directly amenable
to high-throughput screening (HTS). To circumvent this
issue, we employed an assay in which activation of a natural
Nef effector protein (the Src family kinase Hck) is completely
dependent upon the presence of the viral protein. Using this
approach, wewere able to perform a robust, fully automated
HTS campaign. This effort uncovered a unique diphenylpyr-
azolo compound that binds directly to Nef and displays
remarkably potent Nef-dependent antiretroviral activity.
Although a few other small molecules have been reported
that interact with Nef (Dikeakos et al., 2010; Betzi et al.,
2007; Chutiwitoonchai et al., 2011), these compounds are
of lower potency than B9 in cell-based assays for Nef func-
tion, raising the possibility of off-target effects. Further-
more, compounds directed to the Nef-SH3 interface failed
to function in cell-based antiviral assays (Betzi et al., 2007).
In contrast, B9 inhibits Nef-dependent HIV replication in
the submicromolar range and is broadly active against all82–91, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 87
Figure 6. B9 Binding to Nef Requires the
Predicted Binding Pocket Residue Asn126
(A) SPR is presented. Recombinant purified HIV-1
Nef-SF2 was immobilized on the surface of a
Biacore CM5 chip, and B9 was flowed past Nef at
the concentrations shown. The flow path was
switched back to buffer after 180 s to induce B9
dissociation (arrow). The resulting sensorgrams
(black lines) were best fit by a heterogeneous
ligand (Nef in this case) model (red lines) sup-
porting the presence of two distinct binding sites
with KD values of 860 ± 58 nM and 1.72 ± 0.23 nM.
(B) SPR data were also fit by a two-state model,
which yielded a KD value of 1.79 ± 0.11 nM for the
final Nef:B9 complex.
(C) SPR analysis was repeated with wild-type Nef
and three Nef mutants in which Asn126 is replaced
with Leu, Gln, or Ala as shown. B9 was held
constant at 10 mM and bound readily to wild-type
Nef but not to any of the N126 mutants.
(D) Nef Asn126 mutants retain their ability to
activate Hck. Downregulated Hck was assayed
in vitro using the Z0-LYTE kinase assay and Tyr2
peptide substrate either alone or in the presence of
a 10-fold molar excess of wild-type Nef or the
three Asn126 mutants shown. All four Nef proteins
produced an equivalent shift of the Hck activation
curve to the left, indicating that mutagenesis of
Asn126 does not affect its ability to bind and
activate Hck (see also Table S3).
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HTS for HIV-1 Nef AntagonistsM-group HIV-1 Nef variants tested. This potent anti-Nef
activity appears to result from disruption of dimerization, a
Nef property implicated inmanyNef functions.B9 isanattrac-
tive chemical probe for future studies of Nef biology as
well as an exciting lead for antiretroviral drug development.
EXPERIMENTAL PROCEDURES
Recombinant Protein Expression and Purification
Recombinant Hck-YEEI was expressed in Sf9 insect cells as an N-terminal
His-tagged fusion protein and purified as described elsewhere by Trible
et al. (2006). Full-length HIV-1 Nef proteins (SF2 allele; wild-type and Asn126
mutants) were expressed in E. coli with an N-terminal His tag and purified as
described (Trible et al., 2007; Narute and Smithgall, 2012).
In Vitro Kinase Assay and Chemical Library Screening
Screening assays were conducted in 384-well plates in a final volume of 10 ml
per well using the Z0-LYTE kinase assay system and Tyr2 peptide substrate
(Life Technologies) as described elsewhere (Emert-Sedlak et al., 2009).
Compounds were added to each well (20 mM final concentration) and
incubated at room temperature with a preformed complex of Hck-YEEI
(15 ng/well) and Nef (1:10 molar ratio, 75 ng/well) for 30 min. Reactions were
initiated by the addition of ATP (100 mM) and peptide substrate (1 mM), and
incubated at room temperature for 45 min. Reactions were terminated with
5 ml stop reagent as per the manufacturer’s protocol, and fluorescence ratios
were calculated as described elsewhere (Emert-Sedlak et al., 2009; Trible
et al., 2006). The chemical library for this screen was provided to the University
of Pittsburgh Drug Discovery Institute through the NIH MLSCN initiative and
consisted of about 220,000 compounds at the time the primary screen was
initiated. The 1,495 hit compounds from the primary screen were coun-
terscreened for autofluorescence by repeating the assay in the absence of
Hck and Nef proteins. A second counterscreen for development reagent
(protease) inhibitors was conducted against assay reagents and a tyrosine-
phosphorylated Tyr2 control peptide in the absence of Hck and Nef. As per
NIH requirements, the complete set of assay results from the primary screen
has been deposited in PubChem (UID 463187).88 Chemistry & Biology 20, 82–91, January 24, 2013 ª2013 ElsevierHIV Assays
Viral stocks were prepared by transfection of 293T cells (ATCC) with wild-type
and Nef-defective (DNef) proviral genomes (NL4-3 strain) and amplified in the
T cell line, MT2 (NIH AIDS Research and Reference Reagent Program) as
previously described (Narute and Smithgall, 2012; Poe and Smithgall, 2009;
Emert-Sedlak et al., 2009). Viral replication was assessed in the U87MG astro-
glioma cell line engineered to express the HIV-1 coreceptors CD4 and CXCR4
(Narute and Smithgall, 2012; Poe and Smithgall, 2009; Emert-Sedlak et al.,
2009) or in the T lymphoblast cell line, CEM-T4 (Narute and Smithgall, 2012).
Both the U87MG and CEM-T4 cell lines support HIV-1 replication in a
Nef-dependent manner and were obtained from the NIH AIDS Research and
Reference Reagent Program. Compounds were solubilized in DMSO and
added to the cell culture medium 1 hr prior to infection with HIV. Viral replica-
tion was monitored for either 4 days (U87MG) or 9 days (CEM-T4) by
measuring p24 Gag protein levels in the culture supernatant using standard
ELISA-based techniques (Narute and Smithgall, 2012; Poe and Smithgall,
2009; Emert-Sedlak et al., 2009). HIV-1 infectivity was measured using the
reporter cell line, TZM-bl (Platt et al., 1998; Derdeyn et al., 2000) (NIH AIDS
Research and Reference Reagent Program). Cells were grown in 96-well
plates (2.53 104) 8 hr prior to virus infection to permit adherence. Compounds
were preincubated with wild-type HIV-1 for 4 hr prior to addition to the cells in
a final volume of 200 ml. After 48 hr at 37C, the cells were washed with PBS
and lysed in luciferase lysis buffer (Promega) by rocking for 15 min. Lysates
(40 ml) were transferred to white 96-well plates, and 50 ml luciferase reagent
(Promega) was injected into each well. Readings were recorded with a delay
time of 2 s and an integration period of 10 s.
The effect of B9 on Nef-mediated activation of endogenous SFK activity
was evaluated in CEM-T4 cells. Cells (1 3 105) were infected with 50 pg
p24 equivalents/ml of wild-type HIV-1 NL4-3, a Nef-defective mutant
(DNef), or the indicated Nef chimeras in a final culture volume of 10 ml in
the presence of 1 mM B9 or the DMSO carrier solvent alone as
a control. The infected cells were lysed 8 days later, and SFK proteins
were immunoprecipitated with a pan-specific antibody as described else-
where (Narute and Smithgall, 2012). SFK activity was assessed by immuno-
blotting each immunoprecipitate with a phosphospecific antibody against
the activation loop phosphotyrosine residue common to all Src family
members (pY418; Life Technologies). Control blots were performed on cellLtd All rights reserved
Figure 7. B9 Inhibits Nef Dimerization in
Cells
(A) Molecular model of the Nef dimerization inter-
face, based on the crystal structure of the Nef:SH3
complex (Lee et al., 1996). Hydrophobic side
chains that contribute to dimerization are indi-
cated; substitution of these residues with aspar-
tate (Nef-4D mutant) dramatically reduces Nef
dimerization as determined by fluorescence
complementation assay (Poe and Smithgall,
2009).
(B) Human 293T cells were transfected with
Nef-BiFC constructs and incubated with B9
over a range of concentrations. The Nef-4D
mutant was included as a negative control.
Following incubation for 48 hr, the cells were fixed,
stained with a Nef antibody and Texas red, and
analyzed by two-color fluorescence microscopy.
The top panel shows representative images
from cells expressing thewild-type Nef (Nef-WT) in
the absence or presence of B9 (6 mM) as well
as the dimerization-defective mutant, Nef-4D.
The bottom panel shows the result of image
analysis, in which BiFC (Nef dimerization) to
immunofluorescence (Nef expression) intensity
ratios were calculated for at least 150 cells. Data were normalized to the untreated Nef-WT control and represent the mean ± SD.
(C) Nef-4D fails to activate Hck. Downregulated Hck was assayed in vitro using the Z0-LYTE kinase assay and Tyr2 peptide substrate either alone or in the
presence of a 10-fold molar excess of either wild-type Nef or the Nef-4D mutant.
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a loading control.
SIV Assays
Stocks of the pathogenic SIV quasispecies DB670 (Seman et al., 2000) were
the generous gift of Dr. Michael Murphey-Corb, University of Pittsburgh. SIV
replication assays were conducted in CEM-174 cells (Salter et al., 1985). B9
was solubilized in DMSO and added to the cell culture medium 1 hr prior to
infection with SIV. Viral replication was assayed 5 days later as p27 Gag
protein levels by ELISA (ZeptoMetrix). SIV infectivity was measured using
the reporter cell line, TZM-bl, as described above for HIV. B9 was preincu-
bated with SIV for 4 hr prior to addition to the cells.
Cytotoxicity Assays
U87MG or CEM-T4 cells were plated with compounds in DMSO carrier solvent
in 96-well plates and incubated at 37C. After 72 hr, cytotoxicity was assessed
using the Cell Titer Blue reagent (Promega) and the manufacturer’s protocol.
SPR
Recombinant full-length Nef (SF2 strain) with an N-terminal His tag was ex-
pressed in bacteria and purified as described elsewhere (Narute and Smith-
gall, 2012). Nef was then exchanged into HBS-EP buffer (10 mM HEPES [pH
7.4], 150 mM NaCl, 3 mM EDTA, 0.05% v/v P20 surfactant) and concentrated
with an Amicon Ultra 10 kDa molecular weight cutoff spin concentrator. SPR
analysis was performed on a BIAcore 3000 instrument (GE Healthcare) using
a four-channel CM5 biosensor chip at 25C. The Nef protein was covalently
attached to the CM5 chip via standard amine coupling chemistry (Murphy
et al., 2006; Jason-Moller et al., 2006). B9 (as analyte) was prepared in PBS
buffer (10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl) with
1% DMSO and flowed past the immobilized Nef protein channel and a refer-
ence channel on the biosensor CM5 chip at a flow rate of 50 ml/min for 3 min
over a range of concentrations (see Figure 6). The initial binding reaction
was followed by dissociation for 5 min, and the chip surface was regenerated
using HBS-EPD buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA,
0.05% v/v P20, 1 mM DTT) at a flow rate of 50 ml/min for 10 min. The sensor-
gram curves recorded at each B9 concentration were assessed in triplicate,
corrected for buffer effects, and fitted with the heterogeneous ligand-parallel
reaction model using the BIAevaluation 4.1 software suite (GE Healthcare).Chemistry & Biology 20,In this model, one analyte (B9 in this case) interacts with two independent
binding sites on the ligand (two predicted binding sites on Nef in this case),
i.e., A + B1 + B24 AB1 + AB2, where A is the analyte, whereas B1 and B2
represent the independent binding sites. In addition, the data were also fit to
a two-state binding model, in which binding of B9 induces a conformational
change in Nef to stabilize the binding. The two-state model assumes two
states of Nef-B9 complexes, AB and AB*, which correspond to simple binding
of B9 to Nef (AB) and a conformational change to a stable complex (AB*), i.e.,
A + B4AB4 AB*. See Kuroki andMaenaka (2011) for further details of these
SPR data-fitting models.
Molecular Docking
The 3D structure of B9 was docked to the crystal structures of both HIV-1 Nef
(Lee et al., 1996) (PDB 1EFN; without the SH3 domain) and SIV mac239 Nef
(Kim et al., 2010) (PDB 3IK5) in their dimeric conformations using AutoDock
Vina (Trott and Olson, 2010) available at http://vina.scripps.edu. The 3D struc-
tures of compound, B9, and the Nef dimers were first converted from pdb into
pdbqt format usingMGL Tools (Sanner, 1999). The structure of each Nef dimer
was treated as the receptor and was kept rigid during the docking routine. In
contrast, rotatable bonds in the structure of B9 imparted flexibility on the
ligand. A grid box was centered at the 43.76, 18.61, 37.94 (HIV Nef), and
26.43, 7.16, 23.57 (SIV Nef) coordinates with 60 A˚ units in the x, y, and z
directions to cover the entire structure in each case. Docking of B9 to both
Nef dimer structures returned nine lowest-energy conformations of the ligand.
Of these, the Nef:B9 complexes showing the lowest binding energies and the
greatest number of conformations in a cluster were chosen for further study
(see Table S3).
BiFC Assay for Nef Dimerization
The effect of B9 on Nef dimerization was assessed using a cell-based BiFC
assay and our published method (Poe and Smithgall, 2009). Briefly, 293T cells
were plated on glass coverslips and allowed to attach overnight. Cells were
then treatedwith B9 or the DMSO carrier solvent alone for 30min prior to trans-
fection with the Nef-BiFC plasmid pair using XtremeGene9 and the manufac-
turer’s protocol (Roche). Forty-eight hours later, cells were fixed and stained
with anti-Nef antibodies, and immunostained cells were visualized with
secondary antibodies conjugated to Texas red. Two-color immunofluorescent
images were recorded at fixed exposure times for each channel using a Nikon82–91, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 89
Chemistry & Biology
HTS for HIV-1 Nef AntagonistsTE300 inverted microscope with epifluorescence capability and a SPOT
CCD high-resolution digital camera and software (Diagnostic Instruments).
Image analysis was performed to determine mean pixel intensities in the
BiFC (dimerization) and immunofluorescence (expression) channels of
individual cells using ImageJ. BiFC-to-immunofluorescence ratios were
calculated for at least 150 cells from each condition and are presented
as percentage of ratios obtained with DMSO-treated cells expressing wild-
type Nef.
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